|
|
|
|
|
|
Sponsors and Collaborators: |
Dana-Farber Cancer Institute Brigham and Women's Hospital Novartis |
Information provided by: | Dana-Farber Cancer Institute |
ClinicalTrials.gov Identifier: | NCT00165347 |
The purpose of this study is to determine whether or not cancer cells in the body are affected by PTK and whether it affects the growth of these cells.
Condition | Intervention | Phase |
Multiple Myeloma |
Drug: PTK787/ZK222584 |
Phase II |
Genetics Home Reference related topics: | aceruloplasminemia hemophilia |
MedlinePlus related topics: | Cancer Multiple Myeloma |
Drug Information available for: | Vatalanib Butanedioic acid, compd. with N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine (1:1) Tyrosine |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase II Study of PTK787/ZK222584 in Multiple Myeloma |
Estimated Enrollment: | 10 |
Study Start Date: | December 2003 |
Study Completion Date: | October 2006 |
Primary Completion Date: | October 2006 (Final data collection date for primary outcome measure) |
Patients will take PTK orally once a day for the duration of their time on the study. Each cycle of chemotherapy will last for 4 weeks.
Measurement of vital signs will be done weekly during the first month of treatment.
Physical exam, vital signs, blood work, a quality of life assessment, and x-ray or MRI wil be performed every 4 weeks.
Patients will remain on the study until their disease fails to respond to treatment or there are intolerable side effects. Typically treatment is performed for 12 weeks and up to one year in patients that are stable and responding.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Massachusetts | |||||
Dana-Farber Cancer Institute | |||||
Boston, Massachusetts, United States, 02115 |
Dana-Farber Cancer Institute |
Brigham and Women's Hospital |
Novartis |
Principal Investigator: | Nikhil Munshi, MD | Dana-Farber Cancer Institute |
Study ID Numbers: | 03-257 |
First Received: | September 9, 2005 |
Last Updated: | December 20, 2007 |
ClinicalTrials.gov Identifier: | NCT00165347 |
Health Authority: | United States: Institutional Review Board |
|
|
|
|
|